Moreover, there are compelling links between FASN expression and worse oncologic outcomes across multiple tumor types, and a significant interaction with BMI has been noted for both prostate and colon cancer (8, 41), highlighting FASN as a metabolic oncogene. Here, FASN is linked to malignant colon neoplasm.